This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Margaret K. Sparks, MD; Alan N. Moshell, MD; Thomas P. Nigra, MD
Department of Dermatology, 2B-44 Washington Hospital Center 110 Irving St NW Washington, DC 20010

Arch Dermatol. 1985;121(9):1107.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

At the Washington (DC) Hospital Center, seven psoriatic patients who were unresponsive to three weeks of intensive inpatient Goeckerman therapy—ultraviolet-B radiation (UV-B) twice daily and a topical application of tar—have, over the years, been treated with combined therapy, including the combinations of Goeckerman therapy with psoralens and ultraviolet-A (PUVA), with methotrexate, with hydroxyurea (Hydrea), with both PUVA and methotrexate, and with both PUVA and hydroxyurea.

Hydroxyurea, an S-phase mitotic inhibitor, has been used with benefit in psoriasis.^1,2 We have used this agent in combination with UV-B and/or PUVA in five patients. We have observed three patients in whom the combination of hydroxyurea with UV-B was associated with a characteristic pain in psoriatic lesions, which to our knowledge has not previously been described. This pain begins during UV-B therapy and lasts for one to three hours. We herein present three case reports.

Report of Cases.—Case 1.—

A . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?